Fire: Created page with "|- | バルサルタン | Diovan | 6 | 2–4H | 95% | 25% | 30/70% | Yes | 80–320 | 基質: MRP2とOATP1B1/SLCO1B1 |- | イルベサルタン | Avapro | 11–15 | 1.5–2H | 90–95% | 70% | 20/80% | No | 150–300 | CYP2C9のマイナー基質 |- | テルミサルタン | Micardis | 24 | 0.5–1H | >99% | 42–58% | 1/99% | No | 40–80 |..."

2024-03-26T23:56:33Z

Created page with "|- | バルサルタン | Diovan | 6 | 2–4H | 95% | 25% | 30/70% | Yes | 80–320 | 基質: MRP2とOATP1B1/SLCO1B1 |- | イルベサルタン | Avapro | 11–15 | 1.5–2H | 90–95% | 70% | 20/80% | No | 150–300 | CYP2C9のマイナー基質 |- | テルミサルタン | Micardis | 24 | 0.5–1H | >99% | 42–58% | 1/99% | No | 40–80 |..."

New page

|-
| [[Valsartan/ja|バルサルタン]]
| Diovan
| 6
| 2–4H
| 95%
| 25%
| 30/70%
| Yes
| 80–320
| 基質: [[Multidrug resistance-associated protein 2/ja|MRP2]]と[[OATP1B1/ja|OATP1B1/SLCO1B1]]
|-
| [[Irbesartan/ja|イルベサルタン]]
| Avapro
| 11–15
| 1.5–2H
| 90–95%
| 70%
| 20/80%
| No
| 150–300
| [[CYP2C9/ja|CYP2C9]]のマイナー基質
|-
| [[Telmisartan/ja|テルミサルタン]]
| Micardis
| 24
| 0.5–1H
| >99%
| 42–58%
| 1/99%
| No
| 40–80
| 不明; >97% 胆汁排泄
|-
| [[Eprosartan/ja|エプロサルタン]]
| Teveten
| 5
| 1–2H
| 98%
| 13%
| 30/70%
| No
| 400–800
| 不明; >90% 腎と胆汁排泄
|-
| [[Olmesartan/ja|オルメサルタン]]
| Benicar/Olmetec
| 14–16
| 1–2H
| >99%
| 29%
| 40/60%
| No
| 10–40
| [[OATP1B1/ja|OATP1B1/SLCO1B1]]の基質
|-
| [[Azilsartan/jaZ|アジルサルタン]]
| Edarbi
| 11
| 1.5–3H
| >99%
| 60%
| 55/42%
| No
| 40–80
| CYP2C9のマイナー基質
|-
| [[Fimasartan/ja|フィマサルタン]]
| Kanarb
| 7–11
| 服用後0.5–3H
| >97%
| 30–40%
| –
| –
| 30–120
| 不明; 主に胆汁性排泄
|-
! 薬剤
! 製品名
! [[Biological half-life/ja|半減期]] [時間]
! [[Cmax_(pharmacology)/ja|ピーク血漿中濃度[Tmax]]]
! [[Protein binding/ja|タンパク質結合率]] [%]
! [[Bioavailability/ja|生物学的利用能]] [%]
! 腎／肝[[Clearance (medicine)/ja|クリアランス]] [%]
! 食べ物の影響
! 容量/日 [mg]
! [[Metabolism/ja|代謝]]/[[Transport protein/ja|トランスポーター]]
|}

Translations:Angiotensin II receptor blocker/33/ja - Revision history